Objective To study the innovative drug pricing methods and medical insurance payment standards in foreign countries and to provide reference for China’s government.Methods The official websites were searched for info...Objective To study the innovative drug pricing methods and medical insurance payment standards in foreign countries and to provide reference for China’s government.Methods The official websites were searched for information and related literature,and literature review was used.Results and Conclusion In foreign countries,the clinical value of innovative drugs and their impact on medical insurance funds were comprehensively evaluated based on factors such as quality-adjusted life years,clinical benefit,and improvement of clinical benefit.Then,the evaluation results were taken as an important basis for whether innovative drugs were admitted to the medical insurance catalog and establishing medical insurance payment standards.By using international experience for reference,innovative drug pricing methods and medical insurance payment standards for China’s national conditions can be improved by establishing a basic database of clinical value and drug economic evaluation of innovative drugs,as well as innovative drug payment models based on decision thresholds.展开更多
The purpose of this study was to analyze the components of inpatient costs for coronary artery bypass graft(CABG)according to preoperative risk stratification and to provide evidence for improvement of diagnosis-relat...The purpose of this study was to analyze the components of inpatient costs for coronary artery bypass graft(CABG)according to preoperative risk stratification and to provide evidence for improvement of diagnosis-related groups(DRGs)payment.All patients(n=458)receiving an isolated CABG between January 2014 and December 2016 in a tertiary referral center,in southwest China,were analyzed.Hospital mortality was predicted by the EuroSCORE Ⅱ for each patient. The patients were subdivided into two groups according to the observed mortality(1.97%,9/458):a high-risk group(group H,predicted mortality≥1.97%)and a low-risk group(group L,predicted mortality<1.97%).Clinical outcomes,resource use,in-hospital direct costs,and reimbursement expenses were compared between the two groups.Significant differences existed between group L and group H in postoperative mortality(0.4% vs.3.4%;P=0.02),postoperative complications(10.6% vs.45.7%;P<0.001),postoperative length of hospital stay(17.5±4.9 days vs.18.8±6.5 days,P=0.01),in-hospital costs($20 256±3096vs.$23 334±6332;P<0.001),and reimbursement expenses($7775±2627 vs.$9639±3917;P<0.001).In general,a higher EuroSCORE Ⅱ was significantly associated with a worse clinical outcome and increased costs.The CABG cost data provide evidence for improvement of DRGs payment. Key words:coronary artery bypass graft;risk stratification;hospital costs;medical insurance展开更多
Objective To provide reference for China’s medical insurance reimbursement plan of multi-indication drugs.Methods By referring to relevant foreign literature,the implementation process and conditions of different rei...Objective To provide reference for China’s medical insurance reimbursement plan of multi-indication drugs.Methods By referring to relevant foreign literature,the implementation process and conditions of different reimbursement management modes of multi-indication drugs were analyzed to provide suggestions for reimbursement of multi-indication drugs in China.Results and Conclusion It is suggested to further explore the suitable conditions and select the corresponding mode in China.Payment standards should be set according to value pricing and budget impact analysis.Besides,data collection and analysis mechanism must be improved.Lastly,reward and punishment mechanism can be adopted to improve management efficiency.展开更多
目前全国各地积极探索多种形式的医保支付方式,合理有效的医保费用支付方式是医药卫生体制改革的重点内容和关键环节,也是控制医疗费用快速增长和科学有效地使用医保资金的关键所在。研究通过分析对比我国目前已经开展的按项目付费、按...目前全国各地积极探索多种形式的医保支付方式,合理有效的医保费用支付方式是医药卫生体制改革的重点内容和关键环节,也是控制医疗费用快速增长和科学有效地使用医保资金的关键所在。研究通过分析对比我国目前已经开展的按项目付费、按单元付费、按人头付费、按疾病病种付费(diagnosis related groups,DRGs)、总额预付费等医保费用支付方式的不同特点和政策要求,同时对比分析欧美西方发达国家的医保支付管理经验,以求探索、总结先进管理经验,为我国的支付方式改革提供可参考的样本。通过国内外医保付费方式的对比分析发现对我国的启示主要包括探索实施多元复合式医保支付制度、根据病种和诊疗特点实行不同支付方式、实施全面总额控制下的医保支付方式、全面推行以按疾病诊断相关分组(diagnosis related group,DRG)/病种分值付费(diagnosis intervention packet,DIP)为主的多元付费方式。通过对国际改革的政策及实践经验总结分析,进而对我国深化医改和推进医保费用支付方式改革的管理实践起到促进作用。展开更多
目的:对医保药品支付标准相关文献进行可视化分析,总结我国医保药品支付标准领域的研究热点和演进趋势,为进一步完善我国医保药品支付标准提供参考。方法:以(主题词:药品支付标准OR药品支付) AND (主题词:医保OR医疗保险OR基本医疗保险...目的:对医保药品支付标准相关文献进行可视化分析,总结我国医保药品支付标准领域的研究热点和演进趋势,为进一步完善我国医保药品支付标准提供参考。方法:以(主题词:药品支付标准OR药品支付) AND (主题词:医保OR医疗保险OR基本医疗保险)为检索条件,对2000年—2022年中国知网、万方、维普、读秀四个中文数据库检索相关文献,运用Citespace软件进行可视化分析。结果:共检索文献251篇,对医保药品支付标准的研究关注度呈逐步上升趋势,2015年文献发表量激增,2018年—2022年的文献发表数量相对较多。研究机构主要集中于高校,研究机构间合作联系有待加强;研究热点与医保药品支付标准的连接作用、分类制定、动态调整、完善配套政策、形成机制等内容相关。结论:要处理好医保药品支付标准在医疗、医保、医药三者之间的平衡关系,发挥市场在医保药品支付标准形成中的作用,实现分类制定、动态调整,使医保药品支付标准能够真正体现药品质量和价值。展开更多
文摘Objective To study the innovative drug pricing methods and medical insurance payment standards in foreign countries and to provide reference for China’s government.Methods The official websites were searched for information and related literature,and literature review was used.Results and Conclusion In foreign countries,the clinical value of innovative drugs and their impact on medical insurance funds were comprehensively evaluated based on factors such as quality-adjusted life years,clinical benefit,and improvement of clinical benefit.Then,the evaluation results were taken as an important basis for whether innovative drugs were admitted to the medical insurance catalog and establishing medical insurance payment standards.By using international experience for reference,innovative drug pricing methods and medical insurance payment standards for China’s national conditions can be improved by establishing a basic database of clinical value and drug economic evaluation of innovative drugs,as well as innovative drug payment models based on decision thresholds.
文摘The purpose of this study was to analyze the components of inpatient costs for coronary artery bypass graft(CABG)according to preoperative risk stratification and to provide evidence for improvement of diagnosis-related groups(DRGs)payment.All patients(n=458)receiving an isolated CABG between January 2014 and December 2016 in a tertiary referral center,in southwest China,were analyzed.Hospital mortality was predicted by the EuroSCORE Ⅱ for each patient. The patients were subdivided into two groups according to the observed mortality(1.97%,9/458):a high-risk group(group H,predicted mortality≥1.97%)and a low-risk group(group L,predicted mortality<1.97%).Clinical outcomes,resource use,in-hospital direct costs,and reimbursement expenses were compared between the two groups.Significant differences existed between group L and group H in postoperative mortality(0.4% vs.3.4%;P=0.02),postoperative complications(10.6% vs.45.7%;P<0.001),postoperative length of hospital stay(17.5±4.9 days vs.18.8±6.5 days,P=0.01),in-hospital costs($20 256±3096vs.$23 334±6332;P<0.001),and reimbursement expenses($7775±2627 vs.$9639±3917;P<0.001).In general,a higher EuroSCORE Ⅱ was significantly associated with a worse clinical outcome and increased costs.The CABG cost data provide evidence for improvement of DRGs payment. Key words:coronary artery bypass graft;risk stratification;hospital costs;medical insurance
文摘Objective To provide reference for China’s medical insurance reimbursement plan of multi-indication drugs.Methods By referring to relevant foreign literature,the implementation process and conditions of different reimbursement management modes of multi-indication drugs were analyzed to provide suggestions for reimbursement of multi-indication drugs in China.Results and Conclusion It is suggested to further explore the suitable conditions and select the corresponding mode in China.Payment standards should be set according to value pricing and budget impact analysis.Besides,data collection and analysis mechanism must be improved.Lastly,reward and punishment mechanism can be adopted to improve management efficiency.
文摘目前全国各地积极探索多种形式的医保支付方式,合理有效的医保费用支付方式是医药卫生体制改革的重点内容和关键环节,也是控制医疗费用快速增长和科学有效地使用医保资金的关键所在。研究通过分析对比我国目前已经开展的按项目付费、按单元付费、按人头付费、按疾病病种付费(diagnosis related groups,DRGs)、总额预付费等医保费用支付方式的不同特点和政策要求,同时对比分析欧美西方发达国家的医保支付管理经验,以求探索、总结先进管理经验,为我国的支付方式改革提供可参考的样本。通过国内外医保付费方式的对比分析发现对我国的启示主要包括探索实施多元复合式医保支付制度、根据病种和诊疗特点实行不同支付方式、实施全面总额控制下的医保支付方式、全面推行以按疾病诊断相关分组(diagnosis related group,DRG)/病种分值付费(diagnosis intervention packet,DIP)为主的多元付费方式。通过对国际改革的政策及实践经验总结分析,进而对我国深化医改和推进医保费用支付方式改革的管理实践起到促进作用。
文摘目的:对医保药品支付标准相关文献进行可视化分析,总结我国医保药品支付标准领域的研究热点和演进趋势,为进一步完善我国医保药品支付标准提供参考。方法:以(主题词:药品支付标准OR药品支付) AND (主题词:医保OR医疗保险OR基本医疗保险)为检索条件,对2000年—2022年中国知网、万方、维普、读秀四个中文数据库检索相关文献,运用Citespace软件进行可视化分析。结果:共检索文献251篇,对医保药品支付标准的研究关注度呈逐步上升趋势,2015年文献发表量激增,2018年—2022年的文献发表数量相对较多。研究机构主要集中于高校,研究机构间合作联系有待加强;研究热点与医保药品支付标准的连接作用、分类制定、动态调整、完善配套政策、形成机制等内容相关。结论:要处理好医保药品支付标准在医疗、医保、医药三者之间的平衡关系,发挥市场在医保药品支付标准形成中的作用,实现分类制定、动态调整,使医保药品支付标准能够真正体现药品质量和价值。